'Chinese Peptides,' Explained With Data: Imports, Crypto Payments and What Testing Finds

What 'Chinese peptides' means

The phrase describes a supply route, not a substance. It refers to peptides, mostly unapproved ones such as BPC-157 or the investigational weight-loss drug retatrutide, made by chemical manufacturers abroad, overwhelmingly in China, and sold directly to individual buyers rather than through pharmacies. The products are typically labelled 'for research use only' or 'not for human consumption', which is the legal fiction that lets them be sold at all.

China's role is real but ordinary in one sense: it is a global centre of chemical and pharmaceutical-ingredient manufacturing, and the same capacity that supplies licensed drug makers supplies this market. What is unusual is the last step. Instead of selling a bulk ingredient to a regulated manufacturer, a supplier sells a finished vial to a person, who injects it. Everything regulation normally inserts between those two points, from sterility testing to identity checks to a label a doctor can trust, is missing.

The numbers below come from three kinds of source: trade data, blockchain analysis and laboratory testing. Each measures something different, and none of them measures the whole market. A Johns Hopkins report in September 2026 put it plainly: data do not exist to pin down how large the injectable gray market has become ¹.

What the import data does and does not show

The most-quoted figure comes from U.S. customs data cited by The New York Times in January 2026: imports of hormone and peptide compounds from China roughly doubled to $328 million in the first three quarters of 2025, from $164 million in the same period of 2024 ².

That number is easy to misread. The customs category it describes is broad and legal: it includes hormones and peptides imported by licensed manufacturers to make approved medicines, and active ingredients for drugs such as insulin. It does not separate a pharmaceutical company's bulk shipment from a parcel addressed to a consumer, and small consumer packages are the shipments least likely to be declared accurately in the first place.

So the doubling tells you that the flow of these compounds from China grew sharply. It does not tell you how much of that flow ended up in someone's arm outside the regulated system. For that, the clearest available evidence is not trade data at all, but the money trail.

Following the money: the blockchain data

Banks and card processors generally refuse to handle payments for unapproved drugs, so gray-market vendors moved to cryptocurrency. That choice left a public record. In June 2026 the blockchain analytics firm Chainalysis published an analysis of payments to wallets it attributes to peptide vendors ³.

For much of 2024, those wallets received roughly $1 million a quarter. In the first quarter of 2026 they received $32 million, a 159% rise from $12 million in the fourth quarter of 2025, after six consecutive quarters of growth. The firm projected about $39 million for the second quarter, putting the market above a $100 million annual run rate ³.

Chainalysis describes three eras. Before 2025, inflows averaged about $200,000 a month. Growth came with the political attention to alternative health in 2025, which the firm notes coincided with the market's rise without establishing a cause. Then, in late 2025, demand surged as a social-media subculture focused on physical appearance adopted peptides, and the monthly average rose to about $9.9 million, with peak months above $10 million ³.

Two details describe how the trade has professionalised. Larger vendors rely almost entirely on bitcoin and stablecoins, and among vendors averaging $1,000 or more per deposit, stablecoins make up the majority, which shields wholesale orders from crypto's price swings. And many buyers are using cryptocurrency for the first time, which the report says includes underage users asking how to get around identity checks ³.

Why paying in crypto made the market visible

There is an irony at the centre of the data. Vendors adopted cryptocurrency because the banking system would not serve them, and that choice put their entire revenue on a public ledger. A bank transfer to an overseas supplier is visible to the banks involved and to investigators with a warrant. A bitcoin or stablecoin payment is visible to anyone who can attribute the wallets.

That is how a private analytics firm could measure the market quarter by quarter, link vendor wallets to their suppliers, and spot a former fentanyl-precursor supplier reappearing under a new name. It is also why the numbers are a floor rather than a total: they capture only payments made in crypto to wallets that have been identified, and say nothing about vendors paid by bank transfer, payment apps or cash ³.

For a buyer, the practical consequence runs the other way. A crypto payment is permanent, cannot be reversed if a parcel never arrives, and is traceable back to the buyer's own exchange account. The privacy many first-time buyers assume they are getting is largely absent.

Numbers that drifted in the retelling

Coverage of the Chainalysis report produced figures the report itself does not contain. Some outlets described the first-quarter total as a 700% rise on the year before; the report gives a 159% rise on the previous quarter, and does not state a year-on-year percentage. One widely read outlet gave the first-quarter figure as $27 million; the report says $32 million.

None of this changes the direction of the story, which every account agrees on. It changes which numbers can be repeated as fact. The figures on this page are the report's own, read directly, and we would rather give a smaller number we can source than a larger one we cannot ³.

What testing finds, and why buyers stopped doing it

The gray market's informal safeguard has been independent testing: buyers sending a vial to a laboratory to check that it contains what the label says. Chainalysis traced payments to one Czech laboratory widely used for this, and its wallets have received more than $12 million since 2023 ³.

The striking finding is the trend. Early buyers paid to retest what they bought. By the late-2025 boom, testing spend per buyer had fallen an estimated 88%, to about $8. The laboratory is busier than ever, with monthly inflows rising from about $187,000 to about $502,000, because there are far more buyers; each of them is simply testing far less. Many now rely on certificates the vendor supplies ³.

Those certificates have a specific blind spot. They usually report mass and purity, which answers whether the vial contains the right molecule. They often do not test for sterility, which answers whether injecting it could cause an infection. The report describes a batch of retatrutide that carried a passing purity certificate and then failed an independent sterility test submitted by a cautious buyer ³.

Peer-reviewed laboratory work points the same way. European medicines-control laboratories examining suspected illegal health products recorded 1,104 cases from 16 countries between 2017 and 2019, 83% of them from the illegal market ⁴. A European medicines-control laboratory identified the unapproved peptides Selank and Semax in seized preparations and noted how freely they could be bought online ⁵. And an analysis of two commercially sourced custom peptides found 20% and 43% by weight of an undeclared substance, mannitol, invisible to the routine method most purity reports rely on ⁶.

What happens to people who use them

Case reports are not statistics, but they show the failure modes. In 2026, doctors reported an 18-year-old woman who developed euglycaemic ketoacidosis, a dangerous acid build-up with near-normal blood sugar, ten days after starting semaglutide bought online and escalating the dose without supervision ⁷. Another report described a man with type 1 diabetes who developed impending ketoacidosis and acute kidney injury shortly after injecting an online product sold as retatrutide; the authors noted that the composition, purity and dose of such products are uncertain ⁸.

Neither report shows that the product was contaminated, and both patients had other risk factors. What they show is the second danger the gray market creates beyond quality: drugs with real, potent effects taken without the assessment, dose titration and follow-up that come with a prescription. Retatrutide, in particular, is not approved anywhere as of September 30, 2026, and its trial doses were reached by slow escalation under monitoring.

Who is on the other end

The most serious finding in the blockchain data concerns the suppliers. It is important to say, as the report itself does, that most overseas laboratories have no connection to illicit drugs; many are ordinary chemical manufacturers operating in a regulatory blind spot ³.

But some do. Chainalysis traced wallets belonging to Chinese chemical companies previously identified as suppliers of fentanyl and amphetamine precursors, which had received funds from darknet drug vendors and, in one case, from a cartel-linked money-laundering operation. As enforcement against precursor trafficking tightened through 2024, at least two of these companies began selling peptides directly to retail buyers, in one case using the same contact number as their precursor listings, and in another through a separately named corporate alter-ego ³.

The economic logic is plain. Selling precursors, a supplier is a wholesaler and the cartel takes the retail margin. Selling a finished peptide to a consumer, the supplier keeps the whole margin and faces less legal risk. For a buyer, the point is simpler: the label on a research-chemical vial says nothing about who made it, and the money sent for it can reach people a buyer would never knowingly deal with.

What this means if you are considering it

Every source on this page agrees on the core facts: the market is growing quickly, buyers are testing less, the products are unregulated, and some suppliers have links to drug trafficking. What none of them can tell you is whether a particular vial is safe, because nothing in the system is designed to answer that.

Some of the compounds sold this way have approved versions. Semaglutide and tirzepatide are available on prescription, and our guides compare them with what the trials found. Others, such as BPC-157, have no approved version and cannot lawfully be compounded by a US pharmacy as of September 30, 2026; our BPC-157 access guide explains why. Still others, such as retatrutide, are in late-stage trials and approved nowhere.

Our guide to research-use-only labels covers what that phrase does and does not mean, and the certificate decoder explains how to read a certificate of analysis, including what a purity certificate leaves out.

Frequently asked questions

What are 'Chinese peptides'?

Not a type of molecule but a supply route: unapproved peptides made by overseas chemical manufacturers, mostly in China, and sold directly to consumers, usually labelled for research use only.

Are peptides from China safe?

There is no way to know for a particular vial. They are unregulated, buyers have largely stopped independent testing, and vendor certificates usually report purity but not sterility.

How big is the gray market for peptides?

No dataset measures it fully. Blockchain analysis traced $32 million in crypto to peptide vendors in the first quarter of 2026 and projected a $100 million-plus year, which covers crypto payments only.

Do customs figures measure the gray market?

No. The $328 million figure for 2025 covers a broad legal category of hormone and peptide imports, including ingredients for approved drugs, and cannot separate those from consumer parcels.

Are gray-market peptides linked to drug trafficking?

Some are. Blockchain analysis traced several peptide sellers to Chinese companies previously identified as fentanyl and amphetamine precursor suppliers, though most overseas manufacturers have no such link.

Related on Grey Peptides

• What research use only means
• Can a doctor prescribe BPC-157 in 2026?
• Certificate of analysis decoder
• Retatrutide encyclopedia entry
• Regulatory tracker

Sources

1. Johns Hopkins University Hub. The compounding problem of peptides. September 16, 2026. Cited without a link.
2. Sun, J. 'Chinese Peptides' Are the Tech World's Latest Biohacking Fad. The New York Times, January 2026; customs figures as quoted identically by Reason (July 27, 2026) and Foreign Policy (June 8, 2026). Cited without a link.
3. Chainalysis Team. The $100 Million Crypto 'Looksmaxxing' Boom: How Chinese Cartel Suppliers Pivoted to the Gray-Market Peptide Ecosystem. Chainalysis blog, June 4, 2026 (modified June 5, 2026); read September 30, 2026. Cited without a link.
4. Deconinck, E. et al. (2021). The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study. Drug Test Anal. PMID: 33453144
5. Vanhee, C. et al. (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal. PMID: 31667971
6. Choules, M. P. et al. (2020). NMR reveals an undeclared constituent in custom synthetic peptides. J Pharm Biomed Anal. PMID: 31671336
7. Sterckx, M. et al. (2026). Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss. Cureus. PMID: 41773123
8. Branine, N. (2026). Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. PMID: 42669023

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. This article reports market data and published findings; it does not name or link to any seller, and it is not medical advice.